Ranked #1 Children's Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
Kasabach-Merritt phenomenon (KMP) is a complication in which certain vascular tumors trap and destroy platelets. It can be a serious complication because platelets help form blood clots to stop bleeding and patients with KMP are at increased risk of bleeding. KMP may develop in patients with vascular tumors because the tumors reach a certain size or if there is early infection or inflammation. Platelet transfusions can be given to stop significant bleeding or to prevent bleeding during necessary procedures. Otherwise, platelet transfusion should not be given, as they lead to tumor enlargement when new platelets are trapped in the tumor. Platelet counts and KMP improve during therapy for the tumor itself. Tufted angioma is a mild vascular tumor that is rarely complicated by KMP and is likely a mild variant of Kapisoform hemangioendothelioma (KHE). As most cases of KMP involve the tumor KHE, please see KHE for more information.
Kasabach-Merritt phenomenon: Reviewed by Cameron C. Trenor III, MD,
© Boston Children's Hospital, 2015
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”